A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: lapatinib|DRUG: trastuzumab|DRUG: Aromatase inhibitor|DRUG: lapatinib
Sponsor: Novartis Pharmaceuticals
Collaborators: GlaxoSmithKline